Originally published by our sister publication Pharmacy Practice News
Two generic drugs that are key components in many chemotherapy regimens for several different types of cancer are now in such short supply that the FDA, in May 2023, announced that it would allow temporary importation of a non-approved version of one of the medications, cisplatin, from a specific manufacturer and distributor in China.